How Do Patients Feel About Using AI in Health Care?
New research from Yale Cancer Center provides a new understanding of patients’ views of artificial intelligence (AI) in healthcare. While comfort level varied by clinical application, most respondents had positive views about AI’s ability to improve care. Concerns surfaced when potential for misdiagnosis, privacy breaches, reduced time with clinicians, and increased costs were discussed.
Dr. Roy S. Herbst named Chair of the AACR Scientific Policy and Government Affairs Committee
Roy S. Herbst, MD, PhD, has been appointed Chair of the American Association for Cancer Research (AACR) Scientific Policy and Government Affairs Committee; the appointment became effective at the AACR Annual Meeting earlier this week in New Orleans.
New Class of Oncogenic Fusions Revealed in Lung and Pancreatic Cancer
A Yale Cancer Center research team has identified novel oncogenic gene fusions in lung and pancreatic cancer, as well as sarcoma. The fusions involve RASGRF1 (an activator of RAS signaling) and promote cellular changes leading to tumor development. The research is described online ahead of print in Clinical Cancer Research.
Potential Strategies to Fight KRAS Inhibitor Resistance in Lung Cancer Uncovered
Lee and colleagues found that adding an investigational AURKA inhibitor to sotorasib seemed to increase cancer cell death in sotorasib-resistant cancer cells. Adding WEE1 inhibition to AURKA inhibition also seemed to increase cancer cell death. “Our results suggest that AURKA activation may contribute to intrinsic and acquired resistance to sotorasib in KRAS-mutated lung cancer cells and that inhibition of AURKA may be a promising therapeutic approach in this setting,” said Lee.Source: Clinical Omics
Yale Cancer Center’s Dr. Lieping Chen Elected to Prestigious National Academy of Sciences
As one of the highest honors in the scientific field, Lieping Chen, MD, PhD, United Technologies Corporation Professor in Cancer Research, Professor of Immunobiology, Dermatology, and of Medical Oncology, and Co-Director of the Cancer Immunology Program at Yale Cancer Center, was elected to the National Academy of Sciences (NAS).
Yale Study Leads to FDA Approval of Drug to Treat Non-small Cell Lung Cancer
Based on results of a clinical trial led by Yale Cancer Center researchers, the U.S. Food and Drug Administration has approved osimertinib for the treatment of adults with early-stage, non-small cell lung cancer (NSCLC) with EGFR gene mutations, which occurs in about 10 percent of patients.
Yale Cancer Center Researchers Report Results of Afatinib plus Cetuximab for Treatment of EGFR-Mutant NSCLC
Results of a new study led by Yale Cancer Center researchers shows the addition of cetuximab to afatinib versus afatinib alone did not improve outcomes in previously-untreated epidermal growth factor receptor mutant, non-small cell lung cancer.
Atezolizumab Appears Effective for Patients with NSCLC with High PD-L1 Expression
Atezolizumab (Tecentriq) treatment resulted in significantly longer overall survival (OS) compared with platinum-based chemotherapy among patients with non-small cell lung cancer (NSCLC) with high PD-L1 expression, regardless of histologic type, according to results from a phase 3 trial published in the New England Journal of Medicine.Source: Cancer Network
Yale Cancer Center Study Reinforces Benefit Using Targeted Therapy for Early Stage NSCLC
According to updated findings led by researchers at Yale Cancer Center, treatment with the targeted therapy osimertinib following surgery continues to significantly improve disease-free survival (DFS) in patients with early-stage, non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene mutations.
Yale Researchers Tackle COVID-19 and Learn from Patients with Cancer
Across Yale Cancer Center this spring, most research labs shut down to protect their personnel from COVID-19. To protect patients, clinical trial enrollment also took a two month pause. But several of our researchers with relevant expertise have continued to conduct critical research on SARS-CoV-2, the deadly new coronavirus that causes COVID-19.
Yale Pathology Professor Receives NIH Award for Breakthrough Cancer Research
The award — granted to just 5% of NIH-funded investigators —ensures that Kurt Schalper’s research will be funded for the next seven years. It supports his groundbreaking work identifying novel pathways for cancer immunotherapy which can be used to optimally select and treat patients with non-small cell lung cancer.Source: YaleNews
Yale Test of Immunotherapy Drug for Advanced Lung Cancer Shows Promise
Researchers at Yale Cancer Center have found that use of the checkpoint inhibitor pembrolizumab in place of radiation can extend life with very few side effects in patients with advanced metastatic lung cancer.Source: YaleNews
Study: Drug Has Long-term Survival Benefit for Some Lung Cancer Patients
“The response that we have seen from pembrolizumab, in a subset of patients years after treatment ended, is remarkable, especially since their chemotherapy had initially failed,” said Roy S. Herbst, M.D., Ph.D., chief of medical oncology at Yale Cancer Center and Smilow Cancer Hospital and director for translational research at Yale Cancer Center.